Quick FDA action on Synagis

The FDA proved on Friday that it can move fast when it wants to, approving MedImmune Inc.'s Synagis (MEDI-493) humanized monoclonal antibody to treat respiratory syncytial virus (RSV). MEDI submitted the BLA in December 1997.

There had been hints that the approval was forthcoming, and it was widely believed that the FDA was anxious to have the product on the market in time for the fall RSV season...